Drug intelligence / Profile preview

SK-0503 (dexamethasone)

Development stage: Approved
Lead developer: Sanwa Kagaku Kenkyusho
Modality: Small Molecules
Administration: Intravitreal

Overview

SK-0503 is a sustained-release intravitreal implant of dexamethasone developed by Sanwa Kagaku Kenkyusho. It was primarily investigated for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). As a corticosteroid, dexamethasone acts as an agonist of the glucocorticoid receptor, leading to the suppression of inflammatory cytokines, stabilization of the blood-retinal barrier, and reduction of vascular permeability. The program reached Phase 2/3 development in Japan (notably trial jRCT2080221159) but was discontinued by the developer in 2022 due to strategic business considerations.

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on SK-0503 (dexamethasone).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK-0503 (dexamethasone).